GlassScriptPhysician profile
Sergey M Urman
NPI 1972657096
$2,026.40
in general payments reported to CMS, 2019-2025
19 companies · $434 in 2025
The $434 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $22.40 · 2020: $348 · 2021: $70.64 · 2022: $285 · 2023: $331 · 2024: $536 · 2025: $434.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,300.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $455.94 | 2019-2025 | Rocklatan, Clareon, Hydrus Microstent |
| Abbvie INC. | $380.09 | 2022-2025 | Lumigan, Vuity |
| Sun Pharmaceutical Industries INC. | $158.17 | 2023-2025 | Cequa |
| Bausch & Lomb Americas INC. | $150.26 | 2024-2025 | Xiidra, Miebo, Vyzulta |
| Glaukos Corporation | $124.64 | 2020 | |
| Aerie Pharmaceuticals, INC. | $114.48 | 2020 | |
| Horizon Therapeutics Plc | $110.19 | 2023 | Tepezza |
| Allergan, INC. | $95.29 | 2020-2022 | |
| Novartis Pharmaceuticals Corporation | $70.75 | 2020-2023 | |
| Tarsus Pharmaceuticals, INC. | $67.83 | 2024-2025 | Xdemvy |
| Oyster Point Pharma, INC. | $65.71 | 2023-2024 | Tyrvaya, Ryzumvi |
| Amgen INC. | $64.51 | 2024-2025 | Tepezza |
| Ocular Therapeutix, INC. | $38.73 | 2020-2021 | |
| Carl Zeiss Meditec, INC. | $36.11 | 2024 | |
| Dompe US, INC. | $28.80 | 2024 | Oxervate |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn, INC. | $24.97 | 2020 | |
| Harrow Eye, LLC | $22.52 | 2024 | Iheezo |
| New World Medical,INC. | $17.41 | 2023 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sergey Urman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.